JAZZ PATAGONIA (Parkinson’s Disease) This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD […]
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ENVISION Trial The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. What is Alzheimer’s Disease? Alzheimer’s is
PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a
Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Medical Forms Request ShareCare Request Your Medical Records PICK UP IN PERSON OF MEDICAL RECORDS IS NOT AN OPTION AT DENTIF THIS OPTION IS SELECTED ANY APPLICABLE RECORDS WILL BE MAILED. ***IF YOU ARE THE PATIENT AND ARE REQUESTING YOUR OWN RECORDS, PLEASE HAVE YOUR GOVERNMENT ISSUED PHOTO ID READY (license, passport, military ID) AS
